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T cell development comprises a stepwise process of
commitment from a multipotent precursor. To define
molecular mechanisms controlling this progression,
we probed five stages spanning the commitment
process using RNA-seq and ChIP-seq to track
genome-wide shifts in transcription, cohorts of
active transcription factor genes, histone modifica-
tions at diverse classes of cis-regulatory elements,
and binding repertoire of GATA-3 and PU.1, tran-
scription factors with complementary roles in T cell
development. The results highlight potential pro-
moter-distal cis-regulatory elements in play and
reveal both activation sites and diverse mechanisms
of repression that silence genes used in alternative
lineages. Histone marking is dynamic and reversible,
and though permissive marks anticipate, repressive
marks often lag behind changes in transcription.
In vivo binding of PU.1 and GATA-3 relative to epige-
netic marking reveals distinctive factor-specific
rules for recruitment of these crucial transcription
factors to different subsets of their potential sites,
dependent on dose and developmental context.
INTRODUCTION
T lymphocyte development illuminates the stepwise process of
cell fate choice for descendants of multipotent stem cells. Notch
pathway signaling in the thymus causes hematopoietic precur-
sors to become committed to the T cell fate, while mobilizing a
T cell gene expression program that prepares the cells for T cell
antigen receptor (TCR) expression, TCR-based repertoire selec-
tion, and long, versatile careers as immune effectors. Sequential
events that exclude alternative lineages occur at phenotypically
well-defined stages within the thymus, providing a revealing
model for the kinds of events needed to channel multipotent
stem cells into a single developmental path (Rothenberg, 2011;Yang et al., 2010). However,major questions about themolecular
mechanisms involved in this process have remained.
One question is how commitment works. Regulatory genes
that promote access to alternative fates are either expressed
or inducible in the precursors entering the thymus but end up
not only repressed but irreversibly silenced as a result of commit-
ment. Themechanisms responsible for these regulatory changes
have been unknown.
Another question has been how the T cell program is de-
ployed. Notch signaling initiates and sustains differentiation.
T cell development also depends on additional transcription
factors, including E2A and HEB, TCF-1 and LEF-1, GATA-3,
Myb, Runx1, Ikaros, and Gfi1 (reviewed in Rothenberg et al.,
2008). However, it is not clear if this list is complete, and how
these factors work remainsmurky because so few T cell-specific
cis-regulatory elements have been identified. Almost none have
been functionally dissected in enough detail to explain fully the
expression of the genes they control.
In other hematopoietic cell types, key cis-regulatory
sequences of developmental genes have been identified through
the collaborative binding of factors known to confer cell type
identity. For example, combined binding sites of E2A, EBF1,
and/or Pax5 predict cis-regulatory elements in developing Bcells
(Lin et al., 2010; Schebesta et al., 2007). In contrast, no formula
known a priori has been useful to define T lineage-specific cis-
regulatory elements. However, if all the cis-regulatory elements
that are ‘‘in play’’ at crucial transitions of T cell development could
be defined, then the motifs enriched in these elements could be
matched with the cognate transcription factors that also change
at those stages (Novershtern et al., 2011), thus narrowing the
search for the key factors in commitment.
Here, we identify the dynamic transformations in transcription
and epigenetic marking that occur across the genome through
five stages of T cell differentiation that span lineage commitment.
The results provide a genome-wide view of a lineage choice
process in unusually fine resolution. To test the functional
relevance of the histonemarking patterns at potential cis-regula-
tory elements, we also track in vivo binding of GATA-3 and
PU.1, two transcription factors with complementary roles in early
T cell development (Rothenberg and Scripture-Adams, 2008).Cell 149, 467–482, April 13, 2012 ª2012 Elsevier Inc. 467
Recruitment rules for these two factors are revealed to be
context dependent but differently affected by dose. The results
also reveal how an initial regulatory phase dominated by stem/
progenitor-cell regulatory genes first overlaps with Notch
signaling and then is dismantled to establish T cell identity.
RESULTS
Capturing Commitment
Our goals were first to map comprehensively the genes that
undergo transcriptional change during T lineage choice, espe-
cially genes encoding transcription factors, and, second, to
locate likely cis-regulatory sites mediating these gene expres-
sion changes by defining regions where histone marks are
altered at each step of the process.
Cells in the first major stage of T cell development, ‘‘early T cell
precursors’’ orKit2+DN1cells, pass through theDN2astage to the
DN2bstage,when theyundergoT lineagecommitment.Postcom-
mitment, they accumulate in the DN3 stage, during which they
rearrange the TCR genes. Only cells that successfully express
TCR proteins ever proliferate again, differentiating to the DP
(CD4+ CD8+ double-positive) stage in a process called ‘‘b-selec-
tion’’ (reviewed in Rothenberg et al., 2008). Cells are selected
after this based on their TCR recognition specificity, and further
differentiation refines their mature immunological roles.
To obtain enough of the earliest cells for genomic analysis, we
used an in vitro differentiation system that generates copious
yields of early T cell precursors from fetal liver (FL)-derived
hematopoietic progenitor cells. These precursors are cocultured
with lymphoid-permissive cytokines and OP9 stromal cells
expressing a Delta-like Notch ligand (OP9-DL1). In these condi-
tions a cohort of FLDN1 and FLDN2a cells is generated by day
4.5 of culture, mostly progressing to FLDN2b cells by day 8.5
(Figure S1A available online). For an in vivo counterpart, we puri-
fied slightly more advanced DN3 stage cells from freshly isolated
adult mouse thymus, and to show the effects of b-selection, DP
thymocytes were also purified (ThyDN3, ThyDP) (Figures S1B
and S1C; see Extended Experimental Procedures).
In vitro differentiated FL-derived DN1 and DN2 cells showed
gene expression well matched to that of normal in vivo thymo-
cyte counterparts (Yui et al., 2010; David-Fung et al., 2009;
http://www.immgen.org; Heng et al., 2008). Their lineage
commitment status was also in good agreement with that of
in vivo counterparts (Rothenberg, 2011; Yui et al., 2010), as
shown by shifting cells to non-T conditions (Table S1), despite
some minor differences (Table S1 legend). As in adult thymus
in vivo, cells became committed from DN2a to DN2b.
Global Gene Expression Analysis: Selective Changes
during Early T Cell Development
We used RNA-seq (Mortazavi et al., 2008) to identify when major
changes in gene expression occurred along the pathway from
early T cell precursor to DP stages, using two to three indepen-
dent biological replicates each of FLDN1, FLDN2a, FLDN2b,
ThyDN3, and ThyDP cells (Pearson r > 0.97 for independent
replicates of the same stages, Figure S1D). About 10,000 of
the 20,861 Refseq genes were detectably expressed (R1 reads
per kilobase exon model per million reads [RPKM]) in each pop-468 Cell 149, 467–482, April 13, 2012 ª2012 Elsevier Inc.ulation; of these, 50% changed significantly in expression (p <
0.001) between at least one pair of stages and 40% changed
from FLDN1 to ThyDP (Figure 1A).
Figure 1B shows hierarchical clustering of the expression
patterns of the 3,697 genes that change expression by 2-fold
or more between any stages. Between DN1 and DN2b key
T cell-specific genes involved in pre-TCR expression and function
were induced from a low or undetectable level (Table S2), i.e.,
genes encoding TCR complex components Cd3g, Cd3d, Cd3e,
Cd3z (Cd247), T cell-specific signaling components ItkandLat, re-
combinaseRag1,mutagenicDNApolymeraseDntt, and thesurro-
gateachain (pTa)Ptcra. Inaddition,aconspicuousgroupofgenes
were repressedor silencedduring these transitions. They included
progenitor cell-specific growth factor receptor genesKit, Flt3, and
Csf2rb and a set of transcription factor genes described below.
The DN1 to DN2 transition is the first definitive sign of T lineage
entry induced by Notch signaling. However, a much larger
difference was seen between precommitment FLDN2a and
postcommitment FLDN2b cells (2,429 genes different, Figures
1A and 1B) than between FLDN1 and FLDN2a (<900 genes
different), also seen by hierarchical clustering. Conversely,
despite their different origins and manipulation, the newly
committed FLDN2b and ThyDN3 populations were more similar
to each other as well (Figures 1A and 1B). Thus, the major
genome-wide transcriptomic changes leading to T lineage iden-
tity do not occur in the DN1 to DN2a transition, but rather in
transition to the DN2b or DN3 stages, linked with commitment.
Transcription Factor Expression Dynamics in T Lineage
Commitment
Genes likely to encode transcriptional regulators (Table S3A
and Extended Experimental Procedures) included 379 that
changed expression by 2-fold or more (Table S3B). Hierarchical
clustering of their patterns of expression (Figure 1C) again
showed similarities between FLDN1 and FLDN2a and between
FLDN2b and ThyDN3, while the precommitment FLDN2a cells
were more different from the newly committed FLDN2b
(Figure 1C); the ThyDP cells were the most different from all.
Thus, the two major transitions in regulatory gene expression
occur at commitment and at b-selection.
From FLDN1 to FDN2b, the most strongly upregulated ‘‘regu-
latory’’ loci in the whole genome were found to be Lef1 and
Bcl11b (>75-fold increased).Pou6f1,SpiB, Ikzf3, andEts1among
others also increased >8-fold, with weaker increases for Id3,
Tcf12, Gfi1, Tcf7, Hes1, and Gata3 (Table S3B). However, many
regulatory genes sharply decreased in expression between
FLDN1 and FLDN2b, including genes with known, important
functions in hematopoietic progenitors, e.g., Gfi1b, Lmo2,
Mef2c, Hoxa9, Sfpi1 (PU.1), Gata2, Mycn (N-Myc), Cebpb,
Bcl11a, Hhex, Nfe2, Lyl1, and several Irf factors. A major regula-
tory shift, with broad repression of progenitor cell transcription
factor genes, thus accompanies T lineage commitment.
Dynamic Histone Modification Changes Identify
Developmentally Regulated Promoters and Distal
cis-Elements
The specific cis-regulatory elements affected by changing tran-
scription factor action during commitment should be sites of
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Figure 1. Global Comparisons of Gene
Expression among Five Developmentally
Related Immature T Cell Populations
(A) Pairwise comparisons in gene expression
between successive populations and between
initial FLDN1 versus final ThyDP stages: statisti-
cally changed genes defined by DEGseq (p <
0.001). Also see Figure S1 and Table S1.
(B) Hierarchical clustering of expression patterns
of all differentially expressed genes (DEGseq
positive, at least 2-fold changed). Also see
Table S2.
(C) Hierarchical clustering of expression patterns
of differentially expressed transcription factors:
several key transcription factors indicated. Also
see Table S3.developmentally changing histone modifications (reviewed by
Natoli, 2010; Kouzarides, 2007), of greatest interest where they
are linked to differentially expressed genes. We used chromatin
immune precipitation and deep sequencing (ChIP-seq) (Johnson
et al., 2007; Barski et al., 2007) to enrich DNA associated
with three H3 modifications: H3K(9,14)Ac, H3K4me2, and
H3K27me3. Histone H3K(9, 14) acetylation (H3Ac) is functionally
linked to activation at transcriptional start sites (TSSs),
H3K27me3 is used in one mechanism for transcriptional
silencing, and H3K4me2 is associated with activation, poising
for activation or repression, or repression (Orford et al., 2008;
Barski et al., 2007; Johnson et al., 2007; Heintzman et al.,
2007). For many enhancers, H3K4me2 provides more precise
localization than H3K4me1 (Koche et al., 2011). The results
from independent biological replicates again showed excellent
correlation (Figure S1E).
The 42,000 regionswithmarkswere distributed near and distal
to the annotated TSS of expressed and silent genes (Figures 2A
and S2B); Tables S2A (TSS) and S2B (non-TSS) report intensitiesCell 149, 467–4of marking at each stage as correlated
with RNA expression of the nearest
genes. Figure S3 presents these compre-
hensive results for TSSs and non-TSSs
for all Refseq loci in hierarchically clus-
tered heat maps.
Consistent with previous reports, H3Ac
and H3K4me2 were overwhelmingly seen
at promoters of expressed genes. Silent
genes fell into two classes, with only
35% showing H3K27me3 at their pro-
moters. H3K27me3 was more common
at silent regulatory genes than at other
silent loci (Figures 2A and 2B, right).
However, > 25% of the silent genes,
including many with H3K27me3, were
also marked with H3K4me2 (Figures
S2C and S3), consistent with at least
three kinds of repressed states (Filion
et al., 2010). The cumulative frequency
plots in Figure 2C show that genes with
H3K4me2 but not H3Ac at theirpromoters in a given stage (red tracks) (±H3K27me3) were
most likely to be newly repressed or poised for upregulation in
the next stage. Thus, H3K4me2 without H3Ac marks develop-
mentally labile promoters (Koche et al., 2011; Orford et al., 2008).
Histone modification at promoters was relatively stable across
development, more than levels of corresponding RNAs (Fig-
ure S3A). However, distal elements were more dynamically
marked: more than one-third of all regions marked with
H3K4me2 or H3K27me3 in one stage lacked those marks in at
least one other stage (Figure S3B). Thus regulatory shifts occur-
ring in development most sensitively affect histone marking at
nonpromoter elements (Heinz et al., 2010; Lin et al., 2010).
H3K4me2-marked distal elements in fact included a number of
previously noted regulatory elements (Figures S4A and S4B):
the DP-specific Rag1-Rag2 gene antisilencer 71–75 kb 50 of
the Rag2 gene (Yannoutsos et al., 2004), and the DN2b/
3-specific E1a promoter for the Notch1 gene (Go´mez-del Arco
et al., 2010). Both of these discrete cis-elements acquired
H3K4me2 specifically at stages when they contribute to gene82, April 13, 2012 ª2012 Elsevier Inc. 469
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Figure 2. Distinct Gene Expression Patterns Are Associated with Characteristic Histone Modifications
(A) Gene expression and histone modifications at the TSS of 20,861 genes. Expressed (R1 RPKM) and silent (<1 RPKM) genes defined by RNA-seq. Ac: H3Ac,
me2: H3K4me2, me3: H3K27me3. Also see Figures S2 and S3, Table S2.
(B) Gene expression and histone modifications at the TSS of 1,646 genes encoding DNA-binding proteins or transcription factors. Also see Table S3.
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regulation (Figures S4A and S4B). Other non-TSS regions with
developmentally dynamic marking may thus locate stage-
specific cis-regulatory elements as well.
Timing of TSS Epigenetic Changes Relative to
Transcriptional Changes
To relate the timing of changes in TSS marks with changes in
RNA expression during T cell commitment, we focused on
3,697 differentially regulated genes. First, these were subdivided
by K-means clustering into 25 clusters based on expression
pattern (Figure S5; genes listed in Table S4A). Figure 2D tracks
histone marks from stage to stage at the TSS of genes under-
going upregulation (clusters 1, 2, 6), downregulation (clusters
7, 9, 23), and transient decreases (cluster 12) or increases in
expression (clusters 17, 19). H3Ac modification (Figure 2D, first
group of columns) was tightly coordinated with presence of
RNA (last columns), but H3K4me2 was often present before
and after expression (second columns, e.g., clusters 1 and 6).
Though H3K27me3 was inversely correlated with expression,
only a fraction of repressed genes ever acquired this mark (Fig-
ure 2D, third columns), as also seen at promoters genome wide
(Figure S3A).
Most relevant to the regulatory decisions in T lineage commit-
ment (Rothenberg, 2011; Yang et al., 2010) are effects on genes
needed for other hematopoietic cell fates, options that are shed
in an ordered process. We identified 389 key hematopoietic
genes by Gene Ontology (Table S4B), including ‘‘signature’’
regulators of erythroid cells (Gata1, Nfe2, Epor), myeloid cells
(Sfpi1, Cebpa, Cebpe, Csf1r), B cells (Pax5, Ebf1), NK cells
(Eomes, Il2rb), and stem cells (Gata2, Tal1, Lmo2), and tracked
their expression from DN1 to DP in parallel with the status of
histone marks at their promoters (Figure 3). Full results are
shown in Table S4B and the Figure 3 master panel, while
zoom-in panels allow individual genes to be identified. Again,
H3Ac modification at promoters was tightly correlated with tran-
scription, while H3K4me2 marking also preceded and persisted
after transcription.
To explain alternative lineage exclusion in T cell commitment,
either one or diverse mechanisms of silencing of non-T regula-
tory genes might be used. In fact, H3K27me3 use at these
functionally relevant loci was both variable and dynamic. Some
genes were silent throughout T cell specification, and many
had strong H3K27me3 marks at the promoter, either apparently
with H3K4me2 (e.g., Group e, Epor, Irf4, Ebf1, and Eomes) or
without (e.g., Group e, Pax5). Other regulatory genes were
turned off during development, often gaining H3K27me3 while
they lost H3Ac (Group d). Some genes poised for early silencing
already had someH3K27me3 at the TSS fromFLDN1 stage (e.g.,(C) Association of promoter-linked histonemodifications with developmental chan
FLDN2a (top) or ThyDN3 (bottom) stages: H3Ac- H3K4me2+ (H3K27me3+ or) in
green, and H3Ac- H3K4me2- H3K27me3- in black. Cumulative distributions of
FLDN2b (top), and from FLDN2b to ThyDP (bottom). x axis: gene expression chan
right (vertical lines: 2-fold change). y axis: fraction of group with expression change
two-sided tests comparing H3Ac-/H3K4me2+ against each of the other three gr
(D) Heat maps correlating TSS histone modifications with various patterns of d
clusters (see Figure S5, Table S4A). Hierarchical clustering within individual clust
EBF/ pre-pro B cells (H3Ac, H3K4me2, and H3K27me3; ‘‘PPB’’) and CD4+ naCebpa in Group e, Gata2, Lmo1, Tal1 in Group d), suggesting
repression already underway in at least part of the population.
However, H3K27me3 did not mandate future silencing, for
some T cell genes like Lef1 were strongly activated during
commitment despite initially strong H3K27me3 marking (Group
b). Furthermore, other genes stayed silent from FLDN1 to ThyDP
without any H3K27me3 at the TSS (e.g.,Cebpe,Cx3cr1, Zbtb32,
Cd79a, and VpreB1; Group c). Unexpectedly, these variations in
H3K27me3marking cut acrossmyeloid, erythroid, NK cell, and B
cell program boundaries.
Most Epigenetic Change in T Cell Development Occurs
from DN1 to DP
Both the foreshadowing of future expression by H3K4me2
marking of promoters and the ability of some genes to be
repressed without appearance of H3K27me3 (Figures 2D and
3) raised the question of whether we might be missing changes
in promoter status either before DN1, or after DP stage. We
therefore compared our results with H3Ac, H3K4me2, and
H3K27me3 ChIP-seq data for a prethymic lymphoid precursor
population, ‘‘PPB’’ [EBF/ pre-pro B cells (Lin et al., 2010; Heinz
et al., 2010)] and H3K27me3 data for postthymic naive CD4
T cells, ‘‘CD4’’ (Wei et al., 2009), shown in flanking columns in
Figures 2D and 3. The prethymic lymphoid precursor data in
general concurred with the FLDN1 patterns for all three histone
marks. Furthermore, repressed genes that lacked H3K27me3
marks by the DP stage in our samples also remained silent
without H3K27me3 marks in the mature T cells (the uniquely
regulated Rag genes were an exception). The FLDN1 to ThyDP
interval thus encompasses the crucial epigenetic changes for
the great majority of genes affected by T cell specification.
DistinctMechanisms Control Key Developmental Genes
Changes inmodification at distal sites (compiled in Table S2B) as
well as TSSs (Table S2A) often appeared implicated in gene
regulation, as shown for key genes in Figure 4. Figures 4A and
4B profile two highly T cell-specific loci activated in parallel
from DN2a to DN2b, the Cd3gde gene cluster (A) and Bcl11b
(B). These genes initially lack RNA transcripts (black tracks)
and H3Ac marks (blue tracks) in FLDN1 cells, but then are
strongly upregulated and kept on thereafter.
For the Cd3 genes, there was no H3K4me2 (red tracks) at the
promoters and light H3K27me3 marking across the locus (Fig-
ure 4A, green tracks) during the initial silence, but the classic
enhancer elements at the 30 ends of Cd3e and Cd3d (Georgo-
poulos et al., 1988; van de Wetering et al., 1991) were already
marked by focal H3K4me2. These enhancers were already
accessible to transcription factor binding even in the FLDN1ge in expression. Genes are grouped based on histonemarks of their TSS in the
red, H3Ac+ H3K4me2+ H3K27me3- in blue, H3Ac- H3K4me2- H3K27me3+ in
genes in each group are plotted versus expression changes from FLDN1 to
ge (log2 ratio of RNA-seq levels), downregulated to the left, upregulated to the
less than or equal to the x axis value. p values fromKolmogorov-Smirnov (K-S)
oups are shown.
evelopmentally regulated gene expression for nine representative expression
ers used Ward linkage and Euclidean distance. Histone modification data from
ive T cells (H3K27me3 only, ‘‘CD4’’) are also shown for these genes.
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Figure 3. Histone Modifications and Gene Expression Profiles of Genes Characterizing Hematopoiesis
Results for 379 ‘‘hematopoietic’’ genes are processed and displayed as in Figure 2D. Master panel: results for all 379 genes. (a)–(e): zoom in to indicated cluster
regions of master panel to allow individual genes to be seen. Also see Figure S3, Tables S2 and S4B.stage, as shown by binding of the factor GATA-3 (Figure S4C;
see below). Marking of these H3K4me2 sites intensified while
H3Ac and H3K4me2 were recruited to the promoters of the
genes during the DN2a/2b stages, when transcription began. A
similar pattern for activation without initial promoter marking
was seen for Il2ra (Figure S4D).
In contrast to the Cd3gde cluster, the Bcl11b gene (Figure 4B)
began with substantial H3K27me3 (green tracks) over its
promoter and the whole gene body at FLDN1 stage. However,
its TSS had a cryptic positive cis-regulatory element marked
by H3K4me2. Bcl11b then was activated from FLDN2a to
FLDN2b stage through a process that swept back the
H3K27me3 repressive marks off the promoter, while expanding
the H3K4me2 marks into the first intron and creating a new
H3K4me2 marked region in the third intron.
The changes in histone marks at these loci contrast with the
precisely positioned but virtually unchanging H3K27me3,
H3Ac, and H3K4me2 marks that characterized the Gata3 gene
(Figure 4C). Despite a block of H3K27me3 close to the major
promoter, this gene was already activated by the time of the
FLDN1 stage, and underwent only a fewfold increase in expres-
sion after that.472 Cell 149, 467–482, April 13, 2012 ª2012 Elsevier Inc.Repression of essential B cell regulatory factors, myeloid-cell
regulatory factors, and stem or progenitor-cell regulatory factors
is central to T lineage commitment. This clearly entailed a variety
of distinct mechanisms (Figures 4D–4H). The Pax5 gene, crucial
for the B cell program, had no H3Ac modified regions at any
stages (Figure 4D; cf. neighboring Zcchc7 TSS mark). Small
peaks of H3K4me2 marking were seen in intronic regions, one
of them corresponding to a known hematopoietic enhancer
(Decker et al., 2009). However, the gene was buried in
H3K27me3 at all stages. Ebf1 (Figure S4E) was also repressed
from FLDN1 on despite H3K4me2 at several sites.
Hhex and Bcl11a (Figures 4E and 4F), in contrast, were ex-
pressed strongly in FLDN1 cells but then downregulated sharply
by the FLDN2b/ThyDN3 stages, showing evidence of distinct
modulating roles for distal and TSS elements. For Hhex (Fig-
ure 4E), the TSS and two H3K4me2-marked distal regions lost
activation marks as expression decreased, while H3K27me3 ap-
peared focally at the TSS and then spread. A similar pattern was
seen for Flt3 and the Zbtb7b (Thpok) gene, both active in FLDN1
and then repressed (Figures S4F andS4I). ForBcl11a (Figure 4F),
H3Ac persisted at the promoter while RNA expression declined
during commitment, reflecting a tail of low-level expression
through DN3. H3K27me3 marks only appeared at the last stage
of silencing in the DP stage. However, the H3K4me2 modifica-
tion just downstream of the last exon decreased sharply
between FLDN2a and FLDN2b, in parallel with RNA expression,
suggesting a potential regulatory role for a distal element here.
The myeloid and progenitor-cell transcription factor gene
Sfpi1 (encoding PU.1), silenced in parallel with Hhex and never
re-expressed inmost T cell lineages, used a different mechanism
of repression (Figure 4G). H3Ac disappeared from the promoter
while H3K4me2 marks in the upstream cis-regulatory elements
of the gene (Rosenbauer et al., 2006; Zarnegar et al., 2010) nar-
rowed as transcription declined (Figure 4G). Yet minimal
H3K27me3 was ever seen.
Not only were H3K27me3 marks dispensable for repression;
they were also labile. Figure 4H shows that dense H3K27me3
marks on Mpzl2 (same as Eva1) diminished during a spike of
RNA expression in the DN2b and DN3 stages, then returned
during re-silencing in DP stage. Conversely, despite silencing
during commitment, Zbtb7b (Figure S4I) is later activated for
CD4+ cell positive selection.
Early T Cell-Specific Sites for PU.1: A Positive Role
The significance of epigenetic marks depends on their impact on
transcription factor access and their own emplacement via tran-
scription factor binding. We therefore correlated chromatin
marks with binding of GATA-3 and PU.1 (encoded by Sfpi1),
two factors needed for early T cell development, which play
contrasting roles in the context of Notch signals (reviewed by
Rothenberg and Scripture-Adams, 2008; Hosoya et al., 2010).
PU.1 is one of the progenitor-associated transcription factors
in early pro-T cells, but is even more critical for B, dendritic
and myeloid cell development. A key question is whether it has
distinct T lineage target genes or simply carries over a multipo-
tent state.
PU.1 bound to 34,000 sites in DN T cells, comparable to B
and myeloid cells (Heinz et al., 2010). Although PU.1 RNA and
protein levels decline sharply during T lineage commitment (Fig-
ure 5A; Yui et al., 2010), PU.1 site binding preferences remained
consistent from stage to stage. We compared FLDN1 and
FLDN2a cells; FLDN2b cells, where PU.1 is four to five times
downregulated; and DP cells, where PU.1 is absent. Although
PU.1 binding intensity per site was approximately four to five
times lower in the FLDN2b cells, its site choices remained corre-
lated with those in the earlier stages (r = 0.65–0.66) (Figure 5B).
Even so, the PU.1 binding sites in FLDN1 and FLDN2a cells
were distinct from those reported in B cells, macrophages or
even E2A/ pre-pro B cells [representing prethymic lymphoid
progenitors (Heinz et al., 2010; Figure 5C). Although the sites
bound in the pre-pro B cells were most related, key PU.1 target
sites occupied in pre-pro B cells were not bound by PU.1 in
FLDN1 cells, e.g., the intronic enhancer of Pax5 (Figure 5D). De
novo motif analysis showed that PU.1 target sites in FLDN1 cells
had a different hierarchy of preferred sequences than in pre-pro
B cells (Figure 5E). Thus, the consistent site choices of PU.1 from
DN1 stage through commitment include a distinct T lineage-
specific component.
PU.1 is needed to generate T cell precursors, but at high levels
it inhibits expression of many T cell-specific genes, particularly ifNotch signaling is interrupted (Franco et al., 2006). To test
whether the T lineage-specific sites of PU.1 may be repressive,
delaying T cell gene activation in early stages, we asked whether
PU.1 binding specific to early T cells was linked to genes that are
active or silent, as compared with sites bound by PU.1 in pre-pro
B cells but empty in T cells. In fact, the sites occupied by PU.1 in
FLDN1 cells, including FLDN1-specific sites, were mostly asso-
ciated with ‘‘positive’’ marks (H3Ac and/or H3K4me2) and
completely uncorrelated with H3K27me3 marking, more than
sites bound by PU.1 only in E2A/ pre-pro B cells (Figure 5F).
In the aggregate, genes with sites of PU.1 binding in FLDN1 cells
were also more likely to show strong expression, with higher
expression the more sites bound, including T lineage-specific
sites (Figure 5G). Thus, PU.1 binding globally correlates with
target gene expression in FLDN1 cells.
PU.1 Binding Dynamics and Temporal Control of Target
Gene Expression
Experimental perturbation analyses have shown many specific
genes in pro-T cells that are activated or repressed by manipu-
lations of PU.1 level (Franco et al., 2006; A. Champhekar, M.M.
Del Real, and E.V.R., unpublished data). However, with so
many binding sites for PU.1, binding alone clearly could not
define genes that depend on PU.1 for positive or negative regu-
lation. Most PU.1 binding sites were linked to genes expressed
stably in all stages whether PU.1 is present or not, like the
majority of genes expressed in T cell development overall.
PU.1 could thus be opportunistically recruited to many active
genes where it has no required role. To define properties of likely
functional sites, we used the dynamics of PU.1 expression itself
to filter the binding sites identified genome-wide.
Because PU.1 expression declines, functionally important
PU.1 sites should be enriched near genes that themselves
change in RNA expression, up or down, during development
as a function of PU.1 binding. We therefore compared changes
in local PU.1 occupancy from FLDN1 to FLDN2b (Figure 6A)
with the direction and magnitude of changes in RNA expression
of the linked genes, in two complementary ways. First, focusing
only on the PU.1 site-linked genes that change expression from
DN1 to DN2b (Figure 6B), we grouped them according to
whether their linked sites all lost PU.1 occupancy faster (Figures
6B and 6C, blue) or slower (red) than the 4-fold average global
decrease (green = genes with both kinds of sites). Cumulative
frequency plots were used to test if changes in PU.1 occupancy
predicted the direction of changes in gene expression (Fig-
ure 6C), i.e., whether genes losing PU.1 earliest all turn off
like PU.1 itself, or become activated as PU.1 repression might
be relieved. Such analyses could detect both activated and
repressed subgroups within a group as well as general trends.
However, genes that lost PU.1 binding most rapidly (blue curve)
were uniformly more downregulated and less upregulated than
those with mixed sites. Conversely, almost 80% of genes with
sites that retained PU.1 best (red curve) increased their expres-
sion from FLDN1 to FLDN2b.
Second, reciprocally, we classified individual PU.1 sites
according to whether their linked genes were upregulated,
downregulated, stably expressed, or silent across the DN1 to
DN2b interval, and then assessed whether these sites nearCell 149, 467–482, April 13, 2012 ª2012 Elsevier Inc. 473
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developmentally regulated genes tended to lose PU.1 faster or
slower than open but nonregulated sites, i.e., those linked to
stably expressed genes (Figure S6A). Downregulated, upregu-
lated, and stably expressed genes relinquished their PU.1
binding very differently, and sites linked to upregulated genes re-
tained their PU.1 even better than fully ‘‘accessible,’’ stably ex-
pressed ones, again arguing against a repressive role.
At candidate target genes identified both by coregulation with
PU.1 and by PU.1 perturbation effects, PU.1 typically occupied
multiple regions, implying that full PU.1 regulatory function is
commonly mediated through combinations of binding com-
plexes. At Tal1, both PU.1 binding and local H3K4me2 were
lost jointly from three regions, as transcription also declined (Fig-
ure 6D). At the TSS and intragenic regions, PU.1 loss appeared
to open the way for H3K27me3 deposition. Similar patterns
were seen at the TSS of the known PU.1 target Flt3, and at
a downstream element and a known intronic enhancer of Hhex
(Donaldson et al., 2005; Figures S4F and S4G). Other genes
with binding sites that lose PU.1 early include Lmo1 and
Bcl11a as well as Itgam, which decrease naturally from FLDN1
to FLDN2b; all are sharply downregulated in FLDN2 cells if
Sfpi1 is deleted (data not shown; A. Champhekar and E.V.R.,
unpublished data). A PU.1 target with a different pattern of
expression but a similar relation to PU.1 binding was Il7r, which
is upregulated from FLDN1 to FLDN2b. Despite the decreasing
level of PU.1 protein, the Il7r gene retained PU.1 through the
FLDN2b stage, both at a known TSS positive regulatory site
(DeKoter et al., 2002; Xue et al., 2004), and at another putative
cis-element within a silent neighboring gene, Capsl (Figure 6E).
Here too PU.1 regions have a positive link to expression, even
for this gene integral for the T cell program.
Histone Marking and Modes of Action
PU.1 binding can recruit histone methyltransferases and create
locally ‘‘open’’ chromatin states (Ghisletti et al., 2010; Heinz
et al., 2010), and in early T lineage cells as in non-T cells, PU.1
occupancy was dynamically linked with local H3K4me2 modifi-
cation. Due to the developmental stability of H3K4me2modifica-
tion at TSSs, the association was clearest at distal PU.1 binding
regions, where H3K4me2 modification usually melted away as
PU.1 binding decreased (Figures S6B, bottom, and S6D). In
contrast to H3K4me2, PU.1 binding had little overlap with
H3K27me3, even at silent genes (Figures S6C1, S6C12, and
S6D). PU.1 binding-linked H3K4me2 was not simply an effect
of general ‘‘accessibility’’ or expression level of the linked gene
(Figure S6D, ‘‘silent’’ versus ‘‘E2A/’’ sites). Thus, PU.1 occu-
pancy-linked changes in H3K4me2 could be used to screen
candidate distal cis-regulatory regions with PU.1-dependent
activity.
Globally, with or without distal binding sites, PU.1 binding near
the TSS appeared most tightly correlated with a positive roleFigure 4. Portraits of Key T Lineage and Alternative Lineage Genes
(A–H) Distinct epigenetic marking and gene expression patterns at eight different
Sfpi1 (G), andMpzl2 (H), in all five immature T-populations (top to bottom, DN1, D
direction of transcription. H3Ac: blue, H3K4me2: red, H3K27me3: green, RNA-s
scales are uniform within each panel (y axis units in RPM). Also see Figure S4 an(Figure 6F). Genes from diverse expression pattern clusters
(see Figure 2D; Figure S5) could all harbor PU.1 binding either
within the body of the gene or in flanking regions, but differed
sharply in frequencies of genes with PU.1 binding at the TSS
(Figure 6G; Table S6). Genes coregulated with PU.1 itself (cluster
7; also 3, 9, and 23; blue bars) were more likely to have PU.1
binding at the TSS than genes regulated divergently from it
(e.g., clusters 1, 2, 6; red bars) (Table S6B). In contrast, many
T cell genes that can be downregulated by high-level PU.1
(Franco et al., 2006) either had no PU.1 binding in early T cells
or had binding only in the body or flanking regions of the genes.
Genes with particularly low expression in DN1 stage were most
impoverished for PU.1 binding at the TSS (Table S6A, c2 test
p < 0.0001). Thus, PU.1 binding at the promoter may provide,
or indicate, specific antisilencing functions that maintain key
stem and progenitor cell genes in early FLDN1 and FLDN2a
stages.
Developmentally Plastic Deployment of GATA-3 Binding
GATA-3 is needed repeatedly in T cell stages from ETP/DN1
onward and is crucial for T lineage commitment, but capable
of paradoxical effects at high doses (Taghon et al., 2007). Unlike
PU.1, it is expressed almost stably across all the stages analyzed
(Figure 4C; D.D. Scripture-Adams and E.V.R., unpublished data).
We therefore asked whether it controls the same targets in the
distinct regulatory states of FLDN1, FLDN2b, and ThyDP cells.
GATA-3 detectably bound only 1,500 regions (Table S7). In
accord with its recurrent T cell roles, these GATA-3 sites were
enriched for cis-elements of T lineage genes including Cd3d,
Tcf7, Zbtb7b, and the DP-specific Rag1-Rag2 distal enhancer
(Figures S4B, S4C, S4H, and S4I). Occupancy patterns in our
ThyDP samples were broadly consistent with those in DP
CD3lo samples published elsewhere (Wei et al., 2011) (r = 0.60;
Figure S7A). Yet progenitor-specific genes like Lyl1 and Erg
(Figures 7A and 7B) as well as later-expressed T cell genes like
Ets2 and Itk (Figures 7C and 7D) also harbored GATA-3 sites.
Changes in GATA-3 binding were strongly positively corre-
lated with expression trajectories of linked genes both from
DN1 to DN2b and from DN2b to DP (Figure 7E), and also corre-
lated with H3K4me2 modification changes (Figure 7F). GATA-3
bindingwas evenmore likely to be a site of H3K4me2 enrichment
than PU.1 binding (Figure S7B). Yet GATA-3 also bound regions
linked to silent and active genes alike at early stages, and
dramatically differed from PU.1 in its ability to bind regions
with H3K27me3 (Figure S7C). For example, it remained bound
to Zbtb7b even as it became silenced with H3K27me3 (Fig-
ure S4I). Intriguingly, GATA-3 occupancy also preceded full
cis-element activation for Cd3d and the Rag enhancer (Figures
S4B and S4C), suggesting a possible ‘‘pioneering’’ role.
Most unlike PU.1, the distribution of GATA-3 occupancies
among different regions was strikingly different in FLDN1,loci: Bcl11b (A), Cd3e/d/g cluster (B), Gata3 (C), Pax5 (D), Hhex (E), Bcl11a (F),
N2a, DN2b, DN3, and DP) (coordinates below each panel). Red arrow: TSS and
eq: black. Uniform scales are used for histone marks in all panels, and mRNA
d Table S2.
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Figure 5. Lineage-Specific PU.1 DNA Binding Is Associated with Lineage-Specific Histone Modifications and Gene Expression.
(A) Mean RNA-seq level of PU.1 (Sfpi1) at each stage of early T cell development.
(B) (Left) Comparisons of PU.1 DNA binding site distributions between FLDN1 and FLDN2a or FLDN2b, with Pearson’s correlation coefficients (r). (Right)
Comparisons of PU.1 DNA binding-associated H3K4me2 enrichment between FLDN1 and FLDN2a or FLDN2b. H3K4me2 signal densities were from ±1 kb of the
summit of a PU.1 bound region. See Table S5 for all sites.
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FLDN2b, and ThyDP. This was despite nearly constant protein
availability, as shown by similar global occupancy levels and
peak heights at stably occupied sites such as the Tcf3 (Tcfe2a)
promoter (Figure 7D) and the Tcrb 30 enhancer (data not shown)
in all stages. The most common motifs at regions of occupancy
were a classic GATA site and an Ets family-like site (Figure 7G), in
FLDN1, FLDN2b, and ThyDP alike. But from FLDN1 to ThyDP,
GATA-3 occupancy increased sharply in some regions (e.g.,
Ets2 in DN2b, Itk promoter in DP; Figures 7B and 7C), while dis-
appearing from others entirely (e.g., Lyl1, Erg, Itk introns; Figures
7A–7C). Overall, whereas regions occupied in FLDN1 and
FLDN2b stages were moderately well correlated (Pearson r =
0.61), sites in FLDN2b and ThyDP were poorly correlated and
those in FLDN1 and ThyDP entirely uncorrelated (r = 0.0064,
Figure 7H).
These results locate elements in T and non-T genes where the
crucial T cell factor GATA-3 can be contributing to regulation,
from the FLDN1 stage on (Table S7). Nevertheless, they also
reveal that a target gene for GATA-3 at one stage of T cell devel-
opment may not normally receive input from GATA-3 at another
stage, despite similar GATA-3 availability. In contrast to PU.1,
GATA-3’s physiological deployment at any given stage depends
not only on its own availability but also on a specific develop-
mental regulatory context.
DISCUSSION
Our results provide a view of the inner workings of T cell develop-
ment, an instructive reference case for regulatory epigenomics,
and potentially powerful elements needed for explanation of
this complex developmental process. Our global, base-resolu-
tion timecourse of chromatin and transcriptome changes sheds
light on the finely defined stages of T cell specification. The RNA-
seq data not only quantify RNA levels but also provide detailed
information about promoter and exon choice that may affect
gene regulation as well as function. Note that these data also
reveal noncoding transcripts that may be important in various
regulatory roles. Here, we focused on the 400 regulatory
gene loci that themselves are developmentally regulated during
this process, and also the subset of candidate cis-regulatory
genomic sites that undergo developmental changes in histone
modifications, revealing changes in local regulatory inputs.
These are the most likely trans and cis components of nodes in
the gene network that causally drive successive steps of the
T cell program.(C) Comparisons of PU.1 DNA binding between FLDN1 and E2A/ pre-pro B, m
(D) Lineage-specific PU.1 binding at the Pax5 locus. B cell-specific Pax5 introni
(Heinz et al., 2010) (black track), but not in DN cells (brown tracks). PU.1 ChIP-seq
stage is included (red track).
(E) Lineage-specific and shared PU.1 binding sites between FLDN1 and E2A/ p
PU.1 occupancy between populations. Sequence logos show the most highly en
from the three subgroups with one or more instance of each motif are given in
specific).
(F) Distribution of the enrichment of specified histone modification over genom
FLDN1 cells.
(G) Correlation of mRNA expression levels in FLDN1with presence of lineage-spec
genes that are linked to either E2A/ pre-pro B-specific, FLDN1-specific, or shar
FLDN1 cells (Multiple). K-S test compares E2A/ specific only with each of theMost powerfully, the results reveal the subcomponent pro-
cesses out of which T cell specification is built. Relatively few
regulatory genes are strongly activated during lineage commit-
ment itself, and the list is now likely to be complete. Furthermore,
a major feature of commitment is specific, marked downregula-
tion of progenitor-cell genes, through an unexpectedly complex
process. Many important non-T hematopoietic regulatory genes
are still expressed in the precursors we examine through 4 days
of consistent Notch pathway signaling, and many persist even
into the DN2a stage before they are shut off. Importantly, the
histone marking status of the promoters and linked cis-elements
provides an independent line of evidence about the timing and
mechanism of regulatory changes. Loss of H3Ac rules out an
artifact of the decay kinetics of old mRNA persisting after tran-
scription has ceased. Our results also show that the repression
of progenitor-cell genes is not due to a single switch. The diverse
histonemark transformations that are applied to different repres-
sion targets imply that a variety of biochemically and temporally
distinct silencing mechanisms must be used. Notably, this rules
out Notch signaling itself as a commonmechanism of repression
and implies that the T lineage program requires multiple distinct
repressor functions to establish T cell identity.
Dynamically regulated transcriptional repression during this
process is often separable from ‘‘epigenetic silencing.’’ Repeat-
edly, deposition of H3K27me3 histonemarks follows RNA down-
regulation, more likely as an effect and stabilizer of repression
than an initial cause of repression. De novo H3K27me3 marking
appears in two distinct, major patterns. One can be by lateral
invasion from a neighboring patch of pre-existing ‘‘closed’’ chro-
matin, another is by tight focal deposition at a previously active
TSS or enhancer, followed by spreading. In other cases repres-
sion does not involve H3K27me3 at all, possibly due to the nature
of the repressor: e.g., at Sfpi1 and Cd4, two key genes known
to be repressed by Runx factors in DN3 cells. Even when
H3K27me3 is used, it is readily and precisely reversible. Repres-
sion via DNAmethylation was not studied here but is also revers-
ible, as shown recently by the cell type-specific demethylation
of CpGs in DN2-DN3 cells at loci that include Tcf7 and Bcl11b
(Ji et al., 2010) (http://charm.jhmi.edu/hsc/). These examples
show that transcriptional repressors must act first to trigger
chromatin closing, while transcriptional activators retain power
to undo it.
Our results also shed light on the positive regulation of the
T cell program. Despite known essential roles, finding specific
cis-regulatory targets for Notch, GATA-3, and TCF-1 has beenacrophage or mature B cells.
c enhancer is bound by PU.1 (black arrow) in E2A/ pre-pro pre-pro B cells
in ThyDP is used as a negative control. For orientation, H3K4me2 pattern in DN1
re-pro B cells. Lineage specific: greater than or equal to four times difference in
riched sequence motif for each occupancy subgroup. Percentages of regions
parentheses beneath each sequence logo (E2A/ specific/Shared/FLDN1
ic regions within ±1 kb of lineage-specific and shared PU.1 binding sites in
ific or shared PU.1 sites. Distribution of mRNA value in FLDN1 for subgroups of
ed PU.1 binding sites, and genes linked to more than one PU.1 site occupied in
other three subgroups (n and p values in parentheses). Also see Figure S6.
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Figure 6. Functional and Stage-Dependent PU.1 Binding in Early T Cell Development
(A) Stage-specific and non-stage-specific (shared) PU.1 binding sites: stage-specific binding defined by four or more times difference in signal densities between
FLDN1 and FLDN2b.
(B) Differential expression of PU.1 binding linked genes. Top: of 13,335 PU.1 binding linked genes in DN cells, the numbers expressed in FLDN1 (blue circle) and
FLDN2b cells (red circle) are shown (7,244 stably expressed, 1,045 differentially expressed two or more times change). To test whether PU.1 occupancy
correlated with positive or negative regulation, all differentially expressed genes were split among three subgroups based on changes in PU.1 binding to linked
sites (see A): genes with FLDN1-specific sites only (Loss of PU.1 binding in FLDN2b, blue), those retaining PU.1 binding at all sites in FLDN2b (red), and genes that
rapidly lose PU.1 binding from some sites but not others (Mixed, green).
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slow. The identification of a battery of cis-regulatory elements
activated de novo from DN1 to DN2b yields important clues to
clarify these links. GATA-3 effects in early T cells have been
especially difficult to dissect, in part due to the profound loss
of viability when GATA-3 dose is reduced (Hosoya et al., 2009),
and in part due to lineage-inappropriate effects of GATA-3 in
gain of function experiments (Taghon et al., 2007). Identification
of potential GATA-3 regulatory inputs into Tcf7 as well as Tcfe2a
(Tcf3) from the earliest stages suggests a level of regulatory
interlinkage, which could explain the acuteness of the GATA-3
requirement. At least in DP cells, data from Wei et al. (2011)
suggest that the GATA-3 sites we see may positively regulate
Tcf7, Cd3d, and Zfpm1, and could negatively regulate Tcfe2a.
Our results may also help to explain GATA-3’s lineage infidelity
in gain of function experiments by showing that its recruitment
to legitimate target sites, even at a constant level of expression,
is intensely stage specific. Altered dosages could thus override
the mechanisms that must provide appropriate targeting
specificity.
The ordered alternative lineage exclusion events in T lineage
commitment are an ideal context to test whether developmental
relatedness is preserved in a hierarchy of epigenetic chromatin
changes. Clearly, separable events mediate repression of
different alternative lineages. The B cell regulatory genes Pax5
and Ebf1 are silenced by H3K27me3 and rendered inaccessible
to PU.1 binding from the start, whereas the myeloid regulatory
gene Cebpa is bivalently marked. The myeloid and progenitor
regulatory gene Sfpi1 (PU.1), initially fully activated, appears to
play a regulatory role even into the DN2b stage, and is silenced
only when T cell gene expression is under way. However, there is
no simple mapping of developmental lineage exclusion order
with a particular molecular class of repression mechanism.
Drivers of the most ‘‘distant’’ fate in developmental terms, the
erythroid genes, can be repressed via H3K27me3 (EpoR), or
without it (Gata1), as can genes associated with the ‘‘closest,’’
NK-cell fate (Eomes and Il2rb, respectively). In an interesting
additional case, many multipotent progenitor-cell regulatory
genes are expressed throughout the early stages like Sfpi1 and
only shut off during commitment itself. Some may be sustained
by a common progenitor-cell positive regulator, Lmo2 (McCor-
mack et al., 2010), and our results suggest that many receive
input from PU.1 itself. The progenitor-associated genes may
thus constitute a discrete early subcircuit within the T lineage
specification network.
Finally, ourmultistage analysis shows that manymouse hema-
topoietic genes are each likely controlled by different constella-
tions of cis-regulatory elements at one stage of development(C) Relationship between PU.1 occupancy changes and mRNA expression ch
changes for three groups of genes depicted in (B). The number of genes in each gr
the plots. Also see Figure S6.
(D and E) Developmentally distinct PU.1 binding patterns at the Tal1 (D) and Il7ra (
H3K4me2, H3K27me3 and mRNA in all five immature T-populations. Also see Fi
(F) Distribution of PU.1 occupancy relative to TSSs in expressed and silent gene
(G) Location of PU.1 sites in potential target genes according to expression patte
scored by the number of genes they include with PU.1 binding sites ±1 kb from th
a cluster with proximal (,) or distal (>) PU.1 binding. Bar graphs (right axis): (num
expression pattern of each cluster to endogenous PU.1 expression (most similarversus another, even within the same cell lineage. In this light,
the quest for single, minimal sufficient regulatory elements for
such genes seems naive, as it would a priori sacrifice the full
range of developmental control. The roles of the candidate
cis-elements and their rules for engagement with promoters
should be greatly clarified by future extensions of this analysis,
to detect specific chromatin looping events, enhancer activation
states mapped by association with p300 and H3K4me3, and
latent enhancers using H3K4me1 at transcription factor binding
sites. Mechanisms of repression could be clarified when effects
on a broader range of nonactivating cis-elements are mapped
based on DNase hypersensitivity and DNA methylation. The
mapping of developmentally dynamic histone modification
sites provides a guide to locate the sites in cis-regulatory DNA
that process distinct inputs for crucial regulatory genes. In this
collection of regulatory domains lie the answers to how cells
are driven to T lineage commitment.
EXPERIMENTAL PROCEDURES
For full materials, see Extended Experimental Procedures. Briefly, in vitro
developing CD4- CD8- TCR- ‘‘double-negative’’ populations were generated
from fetal liver hematopoietic precursors (Taghon et al., 2007) sorted as
ETP/DN1 (Kit2+ CD44+ CD25-), ‘‘DN2a’’ (Kit2+ CD44+ CD25+), and ‘‘DN2b’’
(Kit+ CD44+ CD25+). ‘‘DN3’’ (Kit- CD44- CD25+) and ‘‘DP’’ (CD25- CD4+
CD8+) cells were sorted from thymus. All mice were maintained and used
under protocols approved by the Caltech Institutional Animal Care and Use
Committee. ChIP-seq and RNA-seq were carried out and analyzed as previ-
ously reported (Pepke et al., 2009; Mortazavi et al., 2008; Johnson et al.,
2007). The programs ERANGE and DEGSeq were used to compare samples.
ACCESSION NUMBERS
All data are deposited under GEO: GSE31235.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
seven figures, and seven tables and can be found with this article online at
doi:10.1016/j.cell.2012.01.056.
ACKNOWLEDGMENTS
We thank Lorian Schaeffer and Vijaya Kumar for library preparation and
sequencing, Henry Amrhein and Diane Trout for data curation, Igor Antoshech-
kin for sequencing facility management, Diana Perez, Josh Verceles, and
Rochelle Diamond for cell sorting and advice, Tian Ling, Georgi Marinov,
and Hao Yuan Kueh for statistical advice and programming, Rothenberg group
members for sharing advice and unpublished data, and Robert Butler, Lorena
Sandoval, and Scott Washburn for care of the mice. Support was from
NIH grants R33HL089123, R01CA090233, R01CA090233-08S1, andanges between FLDN2b and FLDN1: cumulative distributions of expression
oup and p values (K-S tests for comparisons with ‘‘Mixed’’) are indicated next to
E) loci in FLDN1, FLDN2a, FLDN2b, and E2A/ pre-pro B cells, compared with
gure S4.
s at individual stages.
rn. Clusters of genes with different developmental trajectories (Figure S5) were
e TSS (proximal) or further from the TSS (distal).,,> (left axis): % of genes in
ber of genes with TSSs)/(number of geneswith distal sites). Colors of bars relate
: blue, inverse: red). See Figure 2D; Figure S5, and Table S6.
Cell 149, 467–482, April 13, 2012 ª2012 Elsevier Inc. 479
r = -0.027
Lyl1Trmt1 Nfix Itk Tcfe2a
Uqcr11
DN1
DN2a
DN2b
DN3
DP
DN1
DN2a
DN2b
DN3
DP
DN1
DN2a
DN2b
DN3
DP
DN1
DN2b
DPG
A
T
A
-3
  
  
  
  
  
 m
R
N
A
  
  
  
  
  
  
  
  
H
3
K
2
7
m
e
3
  
  
  
  
  
  
H
3
K
4
m
e
2
2
0.02
2
0.02
2
0.02
2
0.02
2
0.02
0.8
0.02
0.8
0.02
0.8
0.02
0.8
0.02
0.8
0.02
10.5
0.02
10.5
0.02
10.5
0.02
10.5
0.02
10.5
0.02
3
0.02
3
0.02
3
0.02
2
0.02
2
0.02
2
0.02
2
0.02
2
0.02
0.8
0.02
0.8
0.02
0.8
0.02
0.8
0.02
0.8
0.02
20
0.02
20
0.02
20
0.02
20
0.02
20
0.02
3
0.02
3
0.02
3
0.02
2
0.02
2
0.02
2
0.02
2
0.02
2
0.02
0.8
0.02
0.8
0.02
0.8
0.02
0.8
0.02
0.8
0.02
7
0.02
7
0.02
7
0.02
7
0.02
7
0.02
3
0.02
3
0.02
3
0.02
2
0.02
2
0.02
2
0.02
2
0.02
2
0.02
0.8
0.02
0.8
0.02
0.8
0.02
0.8
0.02
0.8
0.02
9
0.02
9
0.02
9
002
9
0.02
9
0.02
3
0.02
3
0.02
3
0.02
chr10:79,905,596                  79,862,497chr11:46,211,716                  46,126,052chr16:96,007,217                 95,560,756chr8:87,222,266                 87,234,607
5kb 10kb100kb 20kb
A B C D
HG
Ets2 Erg
46% (8.9%)
44% (18%)
E F
−3 -2 −1 0 1 2 3
0
0.2
0.4
0.6
0.8
1
GATA-3 Enrichment Changes 
(FLDN2b vs. FLDN1) (log2(fold−change))
C
um
ul
at
iv
e 
F
re
qu
en
cy
Downregulated Gene Sites 
(n = 78, p = 6.0e-04)
Upregulated Gene Sites 
(n = 176, p = 7.2e-13)
Stably Expressed Gene Sites (n = 903)
Silent Gene Sites (n = 495, p = 0.15)
−2 −1.5 −1 −0.5 0 0.5 1 1.5 2
C
um
ul
at
iv
e 
F
re
qu
en
cy
H3K4me2 Enrichment Changes 
(FLDN2b vs. FLDN1) (log2(fold−change))
Downregulated Gene Sites 
(n = 78, p = 2.2e-04)
Upregulated Gene Sites 
(n = 176, p = 8.8e-11)
Stably Expressed Gene Sites (n = 903)
Silent Gene Sites (n = 495, p = 2.3e-04)
−3 -2 −1 0 1 2 3
0
0.2
0.4
0.6
0.8
1
GATA-3 Enrichment Changes
 (ThyDP vs. FLDN2b) (log2(fold−change))
C
um
ul
at
iv
e 
F
re
qu
en
cy
Downregulated Gene Sites 
(n = 208, p = 7.2e-11)
Upregulated Gene Sites 
(n = 163, p = 5.5e-06)
Stably Expressed Gene Sites (n = 795)
Silent Gene Sites (n = 486, p = 1.1e-10)
0
0.2
0.4
0.6
0.8
1
−2 −1.5 −1 −0.5 0 0.5 1 1.5 2
C
um
ul
at
iv
e 
F
re
qu
en
cy
H3K4me2 Enrichment Changes 
(ThyDP vs. FLDN2b) (log2(fold−change))
Downregulated Gene Sites 
(n = 208, p = 4.7e-18)
Upregulated Gene Sites 
(n = 163, p = 6.2e-12)
Stably Expressed Gene Sites (n = 795)
Silent Gene Sites (n = 486, p = 7.0e-08)
0
0.2
0.4
0.6
0.8
1
r = 0.61
G
A
T
A
-3
 B
in
d
in
g
 i
n
 F
L
D
2
b
(l
o
g
2
(R
P
M
))
 
GATA-3 Binding in FLDN1 
(log2(RPM)) 
r = 0.22
GATA-3 Binding in FLDN1 
(log2(RPM)) 
G
A
T
A
-3
 B
in
d
in
g
 i
n
 T
h
y
D
P
(l
o
g
2
(R
P
M
))
 
G
A
T
A
-3
 B
in
d
in
g
 i
n
 T
h
y
D
P
(l
o
g
2
(R
P
M
))
 
GATA-3 Binding in FLD2b
(log2(RPM)) 
Figure 7. Developmental Plasticity of GATA-3 DNA Binding and Associated Epigenetic Marking
(A–D) Stage-specific GATA-3 binding (brown) in Lyl1,Ets2-Erg, Itk, and Tcfe2a loci of FLDN1, FLDN2b, and ThyDP cells, shownwith binding associatedH3K4me2
(red) and H3K27me3 (green) enrichment and mRNA (black) expression in all five immature T-populations. Also see Figure S4.
(E) Cumulative distributions of changes in GATA-3 occupancy between FLDN2b and FLDN1 (top) and between ThyDP and FLDN2b (bottom), for genes
differentially regulated across the same intervals. GATA-3 binding sites were divided into four subgroups, based on linkage to downregulated genes (blue),
upregulated genes (red), stably expressed genes (<2-fold change in expression, green) and silent gene sites (<1 RPKM in both stages, black). P values are from
K-S tests between stably expressed gene sites and each of the other three subgroups (n = no. of sites). See Figure S7A, Table S7.
(F) Cumulative distributions of changes in H3K4me2marks associated with GATA-3 binding between FLDN2b and FLDN1 (top) and between ThyDP and FLDN2b
(bottom) stages. H3K4me2 signal densities were calculated within /+1 kb of the summit of a given GATA-3 bound region (depicted in Figure 7H). p values
calculated as in E. See Figures S7B and S7C.
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